Asset profile
PRF-110 · PRF Technologies Ltd. (PRFX)
- Indication
- pain and inflammation following cataract surgery
- Also known as
- PRF-110, OcuRing™-K
Company
PRFXPRF Technologies Ltd.
PRFXPRF Technologies Ltd.PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release …
On the calendar
Nothing scheduled in this window.
Timeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT00883194 | Phase 1/2 | Completed | Apr 1, 2011 | 15 | 0 of 1 sites in the United States |
| NCT05773846 | Phase 3 | Completed | Jul 30, 2024 | 428 | 7 of 7 sites in the United States |